K
Kaku Saito
Researcher at Daiichi Sankyo
Publications - 19
Citations - 896
Kaku Saito is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Trastuzumab & Cancer. The author has an hindex of 7, co-authored 16 publications receiving 354 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun-Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kensei Yamaguchi,DESTINY-Gastric Investigators +16 more
TL;DR: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
Journal ArticleDOI
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani,Hiroji Iwata,Ian E. Krop,Pasi A. Jänne,Toshihiko Doi,Shunji Takahashi,Haeseong Park,Charles H. Redfern,Kenji Tamura,Trisha Wise-Draper,Kaku Saito,Masahiro Sugihara,J. Singh,Takahiro Jikoh,Gilles J. A. Gallant,Bob T. Li +15 more
TL;DR: T-DXd demonstrated promising activity in a heterogeneous patient population with heavily pretreated HER2-expressing or Her2-mutant solid tumors, especially HER2 -mutant NSCLC.
Journal ArticleDOI
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara,Hiroji Iwata,Shunji Takahashi,Kenji Tamura,Haeseong Park,Shanu Modi,Junji Tsurutani,Shigenori Kadowaki,Kensei Yamaguchi,Satoru Iwasa,Kaku Saito,Yoshihiko Fujisaki,Masahiro Sugihara,Javad Shahidi,Toshihiko Doi +14 more
TL;DR: Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in heavily pretreated patients with HER2-positive gastric or gastro-oesophageal junction cancer, and these results support further investigation of trastuzuab derUXtecan.
Journal ArticleDOI
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Kensei Yamaguchi,Y.-J. Bang,Satoru Iwasa,Naotoshi Sugimoto,M-H. Ryu,D. Sakai,H.C. Chung,Hisato Kawakami,Hiroshi Yabusaki,J.W. Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,K. Shitara +15 more
Proceedings ArticleDOI
Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload
Charles A. Powell,Camidge,Akihiko Gemma,Masahiko Kusumoto,Tomohisa Baba,Kazuyoshi Kuwano,A Bankier,Katsuyuki Kiura,Kazuo Tamura,Shanu Modi,Junji Tsurutani,Toshihiko Doi,H. Iwata,Ian E. Krop,Lin Zhang,S Jasmeet,Kaku Saito,Javad Shahidi,Antoine Yver,S. Takahashi +19 more
TL;DR: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload confirms that ILD is an important identified risk for DS- 8201a.